G Protein Coupled Receptors (GPCRs)
===================================

G Protein Coupled Receptors (GPCRs) comprise the largest family of transmembrane receptors, with over 800 members present in humans ([@B65]; [@B87]). GPCRs share a common structure of seven transmembrane helical regions, an extracellular N-terminus and an intracellular C-terminus ([@B4]). Due to this structure, GPCRs are also called 7-Transmembrane receptors (7-TM receptors). While the first description of a crystalline structure of a non-GPCR 7-TM protein was of the bacteriorhodopsin ([@B76]), the first GPCR to have its structure determined was bovine retinal rhodopsin ([@B188]). From the more than 800 human GPCRs, around half have sensory functions that mediate olfaction (about 400), taste (33), light perception (10) and pheromone signaling (5) ([@B167]). Of the remaining non-sensory GPCRs, which account for over 370, more than 90% are expressed in the brain, and mediate signaling from multiple types type of ligands, regulating several physiological processes throughout the human organism, mainly endocrine and neurological processes ([@B89]; [@B207]; [@B171]; [@B4]; [@B97]) ([Figure 1A](#F1){ref-type="fig"}). GPCRs represent the most common target for therapeutic drugs ([@B87]). In 2017, Hauser and coworkers by manually curating the Center Watch's Drugs in Clinical Trials database and by cross referencing with public sources, have identified 475 approved medicine drugs that target GPCRs, which accounted for around 34% of all FDA-approved drugs ([@B87]; [@B235]). This agrees with reports that estimated a proportion ranging from 20 to 50% for drugs that have GPCRs as a target, with discrepancies probably resulting from the varying definitions of "drug target" ([@B89]; [@B207]; [@B126]). As new functions for GPCRs are being discovered, especially for the still around 100 orphan GPCRs for which no endogenous ligand or clearly defined function are currently known, the number of drugs targeting GPCRs is expected to increase ([@B121]; [@B255];[@B126]).

![Relative abundance of G~i/o~-coupled GPCRs. **(A)** GPCRs' main functions. There are about 800 human GPCRs, and around half have sensory functions that mediate olfaction, taste, light perception and pheromone signaling. Another big slice of the pie belongs to non-sensory GPCRs that mediate signaling from other type of ligands, mainly from hormones and neurotransmitters (NTs). **(B)** Relative abundance of G~i/~o-coupled GPCRs in 13 human tissues/regions was taken from the Human Protein Atlas (in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}), quantitatively transformed (value 1 was attributed to 'low', 2.5 for 'medium' and 3.5 for 'high' abundance), and the relative % of tissue distribution calculated by taking the sum of all abundance values, in all the 13 tissues, as 100%.](fnagi-11-00089-g001){#F1}

The first categorization of GPCRs became known as the 'A-F classification system.' Created by [@B119], it divided GPCRs in six classes/families that share some sequence homology and some functional similarities ([@B119]). A seventh class/family ('O') was added later on ([@B255]):

1.  • Family A (rhodopsin receptor family), which includes receptors for odorants, is the largest family of GPCRs and was first divided into three groups (1--3) according to the type of ligand (e.g., small ligands, peptides, high molecular weight hormones such as FSH/TSH/LH) and the GPCR region where to the ligands bind. Currently it has at least 19 known divisions/subfamilies.

2.  • Family B (secretin receptor family) has about 60 members (currently divided in 3 subfamilies), presents a large N-terminal ectodomain and, although lacking the family A structural signature, they have morphological similarities to group A3. Their ligands include low molecular weight hormones such as GH-RH, but mainly polypeptide hormones such as glucagon, calcitonin, and secretin.

3.  • Family C (metabotropic glutamate receptor family) has about 24 members that also have large ectodomains for ligand binding. Besides the different mGluR types, the family also comprises GABA-B receptors and putative pheromone receptors coupled to the heterotrimeric G Protein G~o~.

4.  • Family D (fungus pheromone receptor family) is not found in vertebrates, and contains pheromone receptors (VNs) associated with the heterotrimeric G protein G~i~.

5.  • Family E (cAMP receptor family) is comprised by cAMP receptors (cAR) and is also not found in vertebrates.

6.  • Family F (frizzled/smoothened receptor family) includes the "frizzled" and "smoothened" receptors involved in embryonic development and in cell polarity and division.

7.  • Family O: GPCRs that did not belong to any of the aforementioned families were later on assigned to a new family termed O (for 'Other') ([@B255]).

An alternative classification system, termed "GRAFS," was proposed by [@B65], and divides GPCRs into 5 classes/families according to their primary sequence homology: Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin. The main differences between this nomenclature system and the A-F(O) one are the division of Family B into Secretin and Adhesion families, the inclusion of several unique classified receptor proteins, and the Taste 2 receptors. The Secretin family has 15 members that have an extracellular hormone-binding domain, bind peptide hormones and have conserved cysteine residues that form a network of three cysteine bridges in their N-termini ([@B75]). The Adhesion family is the second largest GPCR family in humans, with 33 members, and has long and diverse N-termini ([@B22]) and a GPCR proteolytic (GPS) domain that Secretin receptors do not have ([@B65]; [@B123]).

Nowadays, pharmacologists generally use the GRAFS sequence similarity family-based classification, supplemented by a ligand-based functional classification. GPCRs usually bind to more than one ligand, but are commonly known according to the main endogenous one, such as dopamine or serotonin, in a third ligand-based classification. This last will be the classification used throughout this review, which will be focused on GPCRs coupled to heterotrimeric G proteins of the G~i/o~ subfamily ([Figure 1B](#F1){ref-type="fig"}).

Heterotrimeric G Proteins of the G~i/o~ Subfamily
=================================================

G protein-coupled receptors are so called since they translate the signal from extracellular ligands into intracellular responses via transducers named 'heterotrimeric G proteins' ([@B210]). Heterotrimeric G proteins are termed as such due to their three subunits: α, β, and γ, with the first being a GTP-binding protein with GTPase activity, and the latter two forming a single inseparable complex usually called the G~βγ~ subunit. Heterotrimeric G proteins are divided into four families according to the functional and structural homologies of their G~α~ subunits, which are responsible for the G~αβγ~ tri-complex main properties: G~i/o~, G~s~, G~q/11~, and G~12/13~ ([@B78]; [@B183]; [@B95]; [@B277]). The G~s~ proteins act as stimulators of adenylyl cyclases (AC), leading to increased levels of cAMP and activation of downstream pathways, including PKA; the G~q/11~ proteins act as stimulators of phospholipase C, which in turns produces the intracellular messengers DAG and IP~3~, resulting in the activation of PKC and calcium signaling; the G~12/13~ proteins act as activators of the RhoA small GTP binding protein and of phospholipase D to regulate cell shape and motility; in contrast, the G~i/o~ proteins are generally described as inhibitory, with AC and potassium channels as their main effectors ([@B179]; [@B165]; [@B277]).

The G~i/o~ family is composed of 8 genes. The three G~i~ proteins, G~αi1~, G~αi2~, and G~αi3~, inhibit some adenylyl cyclase isoforms (with 'i' referring to its inhibitory effect), reducing the ability of basal and G~s~-stimulated AC to generate cAMP. Other members of this family are G~t1~, G~t2~ (transducin) and G~gust~ (gustducin), together with G~z~ and G~o~ proteins. G~t1/2~ and G~gust~ are involved in visual and taste functions, respectively, and activate cGMP-phosphodiesterase. G~z~ inhibits AC, stimulates K^+^ channels and interacts with several protein RGSs. G~z~ is also phosphorylated by protein kinase C (PKC) and p21-activated kinase 1 (PAK1). Finally, the G~o~ protein ('o' standing for 'other') was discovered during G~i~ purification from bovine brain ([@B236]). G~o~ effect on AC is not clear: while initial reports indicated that G~o~ did not inhibit AC ([@B114]; [@B106]), more recent studies point to its ability to inhibit the AC 1 isoform, although not the AC V or VI ones ([@B21]). The G~o~ gene (*GNAO*) transcript is alternatively spliced into G~α1~ and G~α2~ variants, and some studies suggest that G~o~ ability to modulate AC activity is primarily due to its less studied G~o2~ isoform or via its βγ subunit ([@B118]; [@B106]). G~o~ also seems to have a significant role in modulating several other signaling pathways, including the STAT3 and ERK pathways ([@B258]; [@B88]; [@B20]; [@B106]; [@B279]). All of these G~i/o~ family members, except for the G~z~ protein, are inactivated by the pertussis toxin ([@B183]; [@B95]) and all induce K^+^ channels opening, besides functioning via other transduction mechanisms. G~i/o~-coupled GPCRs stimulate GIRK (G-protein activated Inwardly Rectifying K^+^) channels through direct interactions between G~βγ~ and the channel, leading to hyperpolarization and thus decreased neuronal excitability ([@B269]; [@B277]). Importantly, although G~o~ is the most abundant heterotrimeric G protein in the central nervous system (CNS), constituting about 1% of the total membrane protein in the brain ([@B106]), very little is known about its functions, with this being particularly true for the G~α2~ isoform ([@B108]; [@B106]; [@B267]; [@B243]).

In the classical model of activation/deactivation of G proteins, the G~α~ subunit is in an inactive state when bound to GDP, forming a complex with the G~βγ~ subunit. When a ligand binds to a GPCR \[the most common Guanine Nucleotide Exchange Factor (GEFs)\], the receptor changes its conformation and binds to a heterotrimeric G protein, causing a conformational change in the α subunit of the G protein. This causes the exchange of GDP for GTP in the G~α~ subunit and the separation of the α subunit from the βγ ones (and from the GPCR). At this point, the G protein is active and both subunits (G~α~ and G~βγ~) can interact with and modulate the activity of several effector proteins. The G protein signaling is terminated due to the intrinsic GTPase activity of G~α~, which hydrolyzes its GTP to GDP, with consequent re-association of G~α~ to G~βγ~ and inactivation of the G protein ([@B183]; [@B95]; [@B15]). Negative regulators, like Regulators of G protein signaling (RGS), can bind to an activated G~α~ subunit and accelerate its GTPase activity, leading to a faster inactivation and reassembling of the heterotrimeric G protein ([@B50]; [@B94]; [@B137]) ([Figure 2A](#F2){ref-type="fig"}).

![GPCR and G-proteins activation models. **(A)** Classical GPCR/G protein activation model. When inactive, heterotrimeric G proteins exist as a complex comprising the α subunit (bound to GDP) and the βγ subunit. (1a) The binding of a ligand (as a neurotransmitter) to a GPCR results in a conformational change that allows (1b) the binding of the receptor to the G protein. (2) This in turn causes a second conformational change on the α-subunit that results in the exchange of its GDP by GTP, and the separation of the α and βγ subunits. (3) At this point the G protein is active, and both the α and βγ subunits interact with downstream effectors to modulate different signaling pathways. (4) The G protein activation is terminated by the hydrolysis of the GTP molecule into GDP, a reaction that can be accelerated by the binding of Regulators of G-protein Signaling (RGS) to the α subunit. (5) The GTP hydrolysis results in the re-formation of the trimeric complex, bringing the G protein back to its inactive state. **(B)** Pre-coupled model(s). New mechanisms of GPCRs' activation have emerged from various studies, particularly on G~i/o~-coupled GPCRs. In these, inactive GPCRs monomers (left) or homo/hetero dimers (right) exist in an inactive G protein-binding state. In some cases, effector proteins (as adenylyl cyclase, AC) can even be part of the inactive pre-coupled receptorsome complex (not shown). (1) When the GPCR is activated by a ligand (as dopamine, serotonin, etc.) (2) its coupled G protein becomes active by exchanging GDP by GTP and either dissociates from the GPCR and its βγ subunit to initiate the signaling response (left) or remain associated to the complex and activate downstream effector proteins at the membrane (right). (3) In either case, the GTPase activity (accelerated, e.g., by binding to RGS proteins) terminates the activation cycle for that G protein, and the GPCR-inactive G protein complex reassembles/is reinstalled. Note that, in both classical and pre-coupled models, when an active G~α~ subunit dissociates from the GPCR, another cytosolic inactive heterotrimeric G protein can bind to the activated GPCR to get activated, in an amplification mechanism. GIRK, G-protein activated Inwardly Rectifying K^+^ channel; PLC, phospholipase C; PDE 6, phosphodiesterase 6.](fnagi-11-00089-g002){#F2}

Alternatively, a pre-coupled model ([Figure 2B](#F2){ref-type="fig"}) has gained ground, particularly for G~i/o~-coupled GPCRs, the focus of this review. In this, inactive GPCRs in the rest state are in a heterotrimeric G protein-binding state from which they dissociate when activated. When this occurs, the G protein is also activated, exchanges GDP by GTP in the G~α~ subunit, and initiates the signaling response. This also allows for the active GPCR to bind to another G protein, in a catalytic activation and signal amplification cycle ([Figure 2B](#F2){ref-type="fig"}). This GPCRs-G protein pre-coupled model explains why GPCRs have high affinity binding to agonist ligands in the absence of GTP, and why many G~i~-coupled GPCRs can be co-purified with bound inactive G~i~ protein ([@B35]; [@B82]; [@B176]).

Indeed, several evidence have emerged supporting other activation models than the classical one, including observations that (1) GPCRs can form either hetero- or homodimers and create functional pre-coupled complexes with heterotrimeric G proteins in the rest state ([@B84]; [@B192]; [@B63]; [@B178]; [@B205]; [@B58]; [@B175]; [@B252]; [@B31]); (2) the G proteins can exist in a pre-coupled complex with the GPCR and an effector protein, as AC; further, binding of agonists to GPCR might result in the activation of the G protein without its dissociation from the complex ([@B62]; [@B175]); (3) some G~α~ subunits can interact and modulate downstream signaling even when bound to GDP ([@B112]; [@B137]); (4) newly identified modulators of G protein activity, called GEMs (guanine exchange modulators), can activate and inhibit different G~α~ subunits through the same motif ([@B81]; [@B69]).

Brain-Enriched GPCRs Coupled to G~i/o~
======================================

Many of the physiological roles of GPCRs are determined by the heterotrimeric G proteins to which they couple ([@B191]; [@B147]). The coupling between GPCRs and the G~i/o~ family is of particular interest in the brain since G~i/o~ proteins are generally inhibitory, decreasing neuronal excitability, and can be the target not only for, e.g., analgesics, antipruritics, but also for several modulatory medications ([@B277]). Further, the oligomerization properties that are emerging for some of these GPCRs, together with the high abundance of G~o~ in the CNS ([@B106]) and its less understood functions and signaling mechanisms, all these made G~i/o~-coupled GPCRs the central topic of this review.

From all GPCRs, 21.9% couple exclusively to the G~i/o~ subfamily, and other 5% can couple to proteins of the G~i/o~ and of other G subfamilies. Almost all of these GPCRs belong to the Glutamate and Rhodopsin families ([@B184]), but some receptors of the F/Frizzled/smoothened family also have been reported to couple to G~i/o~. These include G~i~-coupled smoothened receptors signaling for Sonic Hedghog ([@B203],[@B204]; [@B34]; [@B42]; [@B93]) and Frizzled 6 Wnt receptor ([@B115],[@B116]; [@B12]). Noteworthy, all these receptors may couple differentially among different G~i~ and G~o~ isoforms, and specifically prefer one specific isoform to the other(s) ([@B108], [@B107]; [@B106]; [@B267]; [@B243]), a topic that should be further explored by researchers.

Data regarding the relative protein abundance of G~i/o~-coupled GPCRs in human tissues was obtained from 'The Human Protein Atlas' database (v16.1.proteinatlas.org) ([@B256]), and is presented in the [Supplementary Table S1](#SM1){ref-type="supplementary-material"}. A short summary of this table's information is here shown as a relative abundances chart ([Figure 1B](#F1){ref-type="fig"}). This chart reveals that GPCRs coupled to G~i/o~ have a wide distribution pattern throughout various human body tissues/regions, being present in virtually all human tissues in relevant amounts. Nevertheless, [Figure 1B](#F1){ref-type="fig"} also indicates that G~i/o~-coupled GPCRs are highly abundant in the brain, hematopoietic and immune system, lung, gastrointestinal tract, endocrine tissue and reproduction systems, while being slightly less abundant in pancreas, adipose and other soft tissues. Based on this graph we have further focused this review on G~i/o~-coupled GPCRs highly abundant in the brain (with a 'high' relative abundance in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}) and/or with high brain specificity (present in no more than 4 tissues other than brain). These criteria retrieved the following 12 GPCRs: adrenoceptors, dopamine receptors, acetylcholine receptors, serotonin receptors, purinoceptors, opioid receptors, somatostatin receptors, angiotensin receptors, cannabinoid receptors, leukotriene receptors, metabotropic GABA receptors, and metabotropic glutamate receptors. Lysophospholipid receptors are also highly abundant in brain but also in various other body tissues, and were here excluded.

G~i/o~-coupled GPCRs have several functions within the nervous system, and a better understanding of the mechanisms regulated by these receptors is essential for the search of new therapeutic targets ([@B138]). The functions of G~i/o~-coupled GPCRs can be detected and studied at a molecular and cellular level, such as neurite outgrowth, neurotransmitter release and synaptic plasticity, which are then translated into complex brain functions, such as memory, learning, and cognition. Serotonin, dopamine, cannabinoid, and metabotropic glutamate receptors are involved in mechanisms of short and long-term memory, memory consolidation, and learning ([@B1]; [@B132]). Opioid and serotonin receptors are involved in the perception and processing of pain ([@B55]; [@B53]). Most GPCRs, including dopamine, serotonin, and opioid receptors also play a prominently role on modulating and influencing behavior and emotions ([@B14]; [@B44]; [@B174]). Sleep and the regulation of the circadian rhythm are also highly regulated by GPCRs signaling, although it is not clear if the main GPCRs involved act through the G~i/o~ family ([@B45], [@B46]; [@B254]). Additionally, GPCRs play a crucial role on brain development, by modulating different mechanisms, such as neuronal migration, neurite outgrowth and axonal elongation. Some of the GPCRs responsible for these actions include somatostatin, dopamine, and cannabinoid receptors ([@B131]; [@B127]; [@B141]; [@B278]). A detailed list of G~i/o~-coupled GPCRs functions on the nervous system can be found in [Table 1](#T1){ref-type="table"}.

###### 

Brain-enriched and/or neurological-relevant GPCRs that can couple to the Gi/o subfamily, and their functions.

  Receptor classes                   Gα protein          GPCRs' ligand(s) and general functions; subtypes and their specific functions   
  ---------------------------------- ------------------- ------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Adrenoceptors                      α2A (ADRA2A)        Gi and Go                                                                       **Ligand:** Adrenaline \> noradrenaline
                                                                                                                                         • Their activation causes platelet aggregation, blood vessel constriction and constriction of vascular smooth muscle;
                                     α2B (ADRA2B)                                                                                        • Presynaptically, these receptors inhibit the release of noradrenaline (negative feedback control);
                                                                                                                                         • **α2B and α2C:** positive regulation of neuronal differentiation.
                                     α2C (ADRA2C)                                                                                        
  Dopamine receptors                 D2 (DRD2)           Gi/Go                                                                           **Ligand:** Dopamine
                                     D3 (DRD3)                                                                                           • Their activation mediates inhibitory dopaminergic neurotransmission;
                                     D4 (DRD4)                                                                                           **D2:** important in the reward effects of morphine; knockout mice exhibit abnormal synaptic plasticity and display reduced levels of aggression; adenohypophysis development; associative learning; axonogenesis; branching morphogenesis of nerves; cerebral cortex GABAergic interneuron migration; chemical synaptic transmission, postsynaptic; long-term memory; negative regulation of synaptic transmission, glutamatergic; neurological system process involved in regulation of systemic arterial blood pressure; neuron-neuron synaptic transmission; orbitofrontal cortex development; positive regulation of dopamine uptake involved in synaptic transmission; positive regulation of glial cell-derived neurotrophic factor secretion; positive regulation of long-term synaptic potentiation; positive regulation of neuroblast proliferation; prepulse inhibition; regulation of dopamine uptake involved in synaptic transmission; regulation of long-term neuronal synaptic plasticity; regulation of synapse structural plasticity; regulation of synaptic transmission, GABAergic; response to axon injury; striatum development; synapse assembly; synaptic transmission, dopaminergic; visual learning.
                                                                                                                                         **D3:** their distribution is consistent with a role in cognition and emotional functions; implicated in modulation of cocaine self-administration; promotes cell proliferation**;** learning or memory; negative regulation of oligodendrocyte differentiation; prepulse inhibition; regulation of dopamine uptake involved in synaptic transmission; synaptic transmission, dopaminergic; visual learning.
                                                                                                                                         **D4:** may be involved in the modulation of gastric acid secretion; responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior; modulates the circadian rhythm of contrast sensitivity and inhibits adrenergic receptor-induced melatonin synthesis by α(1B)-D~4~ and β~1~-D~4~ receptors heterodimerization; knockout mice are supersensitive to several psychoactive substances, including ethanol, cocaine, and methamphetamine; inhibitory postsynaptic potential; positive regulation of dopamine uptake involved in synaptic transmission.
  Acetylcholine receptors            M2 (CHRM2)          Gi and Go                                                                       **Ligand:** Acetylcholine
                                     M4 (CHRM4)                                                                                          • Their activation mediates many of the effects of acetylcholine in the central and peripheral nervous system;
                                                                                                                                         • Seem to function as autoreceptors;
                                                                                                                                         • Knockout mice reveal an important neuromodulatory role for these receptors;
                                                                                                                                         **M2:** control of myocyte contraction; smaller role in the smooth muscle contractile response; may be involved in the regulation of body temperature; nervous system development; synaptic transmission, cholinergic;
                                                                                                                                         **M4:** inhibitory autoreceptor for acetylcholine; activation of the receptor in the striatum inhibits dopamine-induced locomotor stimulation in mice; synaptic transmission, cholinergic.
  Serotonin receptors                5-HT1A (HTR1A)      Gi/Go                                                                           **Ligand:** Serotonin
                                     5-HT1B (HTR1B)                                                                                      • **5-HT1A:** autoreceptors that inhibit cell firing; involved in many neuromodulative processes; implicated in the neuroendocrine regulation of adrenocorticotropic hormone (ACTH); role in the regulation of 5-hydroxytryptamine release, metabolism and levels in the brain -- thereby affects neural activity, mood and behavior; plays a role in the response to anxiogenic stimuli;
                                     5-HT1D (HTR1D)                                                                                      • **5-HT1B:** induce presynaptic inhibition and influence behavior; vascular effects, such as pulmonary and cerebral arteries vasoconstriction; may also have a role in the regulation of bone; regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior; chemical synaptic transmission; negative regulation of synaptic transmission, GABAergic; negative regulation of synaptic transmission, glutamatergic;
                                     5-HT1E (HTR1E)                                                                                      • **5-HT1D:** affect locomotion and anxiety; involved in vascular vasoconstriction in the brain; implicated in feeding behavior, anxiety, depression; may have a stimulatory effect on growth hormone secretion; regulates the release of 5-hydroxytryptamine in the brain, and thereby affects neural activity; chemical synaptic transmission;
                                     5-HT1F (HTR1F)                                                                                      • **5-HT1E:** exact function is presently unknown, due to the lack of selective ligands; may have an important evolutionary role in humans and may be involved in the regulation of memory; chemical synaptic transmission;
                                     5-HT5A (HTR5A)                                                                                      • **5-HT1F:** chemical synaptic transmission;
                                                                                                                                         • **5-HT5A:** may play a role in sleep and serve as a presynaptic serotonin autoreceptor; chemical synaptic transmission.
  Purinoceptors                      P2Y12 (P2RY12)      Gi/Go                                                                           **Ligand P2Y12 e P2Y13:** ADP
                                                                                                                                         **Ligand P2Y14:** UDP-glucose
                                     P2Y13 (P2RY13)                                                                                      **P2Y12:** role in amplification of platelet activation and aggregation and blood coagulation; glial cell migration; regulation of microglial cell migration;
                                     P2Y14 (P2RY14)                                                                                      **P2Y13:** may play a role in hematopoiesis and the immune system.
  Opioid receptors                   δ (DOR-1)           Gi and Go                                                                       **Ligand delta (δ):** β-Endorphin, met/leu-enkephalin
                                     κ (KOR-1)           Gi/Go                                                                           **Ligand kappa (κ):** Dynorphin A
                                     μ (MOR-1)                                                                                           **Ligand mu (μ):** β-Endorphin \> Dynorphin A \> met/leu-enkephalin
                                     OPRL1                                                                                               **Ligand OPRL1:** Nociceptin/orphanin FQ
                                                                                                                                         • **δ:** role in the perception of pain and in opiate-mediated analgesia; developing analgesic tolerance to morphine; chemical synaptic transmission; neuropeptide signaling pathway;
                                                                                                                                         • **κ:** are believed to mediate analgesia and sedation (perception of pain), miosis and dieresis; role in mediating reduced physical activity and regulation of salivation upon treatment with synthetic opioids; may play a role in arousal and regulation of autonomic and neuroendocrine functions; chemical synaptic transmission; neuropeptide signaling pathway;
                                                                                                                                         • **μ:** are believed to mediate analgesia, hypothermia, respiratory depression, miosis, bradycardia, nausea, euphoria, and physical dependence; involved in neurogenesis; chemical synaptic transmission; neuropeptide signaling pathway; positive regulation of neurogenesis;
                                                                                                                                         • **OPRL1:** potential role in modulating various brain functions, including instinctive behaviors and emotions; role in modulating nociception and the perception of pain; regulation of locomotor activity by the neuropeptide nociception; chemical synaptic transmission; neuropeptide signaling pathway.
  Somatostatin receptors             SSTR1               Gi and Go                                                                       **Ligand SSTR1-4:** somatostatin-14 = somatostatin-28.
                                     SSTR2                                                                                               **Ligand SSTR5:** somatostatin-28 \> somatostatin-14.
                                     SSTR3                                                                                               • **SSTR1:** cerebellum development; forebrain development;
                                     SSTR4                                                                                               • **SSTR2:** growth hormone secretion; glucagon secretion; immune responses; mediates the inhibitory effect of somatostatin-14; inhibits cell growth; stimulates neuronal migration; stimulates axon outgrowth; neuronal development and maturation; mediates negative regulation of insulin receptor signaling through PTPN6; inactivates SSTR3 receptor function; cerebellum development; forebrain development;
                                     SSTR5                                                                                               • **SSTR3:** inhibition of angiogenesis; cerebellum development; forebrain development; chemical synaptic transmission; neuropeptide signaling pathway;
                                                                                                                                         • **SSTR4:** arachidonate release; activation of mitogen-activated protein kinase cascade; anti-proliferative action in tumor cells; cerebellum development; forebrain development;
                                                                                                                                         • **SSTR5:** GH secretion; insulin secretion; increases cell growth; chemical synaptic transmission.
  Angiotensin receptors              AT1 (AGTR1)         Gi/Go, Gq/11, G12/13                                                            **Ligand:** Angiotensin II \> Angiotensin III
                                                                                                                                         • Their activation mediates the cardiovascular effects of angiotensin II and angiotensin III (vasoconstriction, heart rate, aldosterone secretion, blood pressure, and volume);
                                                                                                                                         • Regulation of cell proliferation.
  Cannabinoid receptors              CB~1~ (CNR1)        Gi and Go                                                                       **Ligand:** Anandamide and 2-arachidonoyl glyceride
                                     CB~2~ (CNR2)                                                                                        • **CB~1~:** inhibition of ongoing release of excitatory and inhibitory neurotransmitters; axonal fasciculation; memory; negative regulation of action potential; positive regulation of neuron projection development; regulation of synaptic transmission, GABAergic and glutamatergic; *trans*-synaptic signaling by endocannabinoid, modulating synaptic transmission; negative regulation of dopamine secretion;
                                                                                                                                         • **CB~2~:** effect on the immunological activity of leukocytes; immune suppression; induction of apoptosis; induction of cell migration; negative regulation of action potential; negative regulation of synaptic transmission, GABAergic.
  Leukotriene receptors              LTB4R               Gi/Go and Gq/11                                                                 **Ligand:** Leukotriene B4
                                     LTB4R2                                                                                              • **LTB4R:** may be the cardiac P2Y receptor involved in the regulation of cardiac muscle contraction; act as a co-receptor; for macrophage-tropic Human immunodeficiency virus 1 (HIV-1) strains; causes chemotaxis; neuropeptide signaling pathway;
                                                                                                                                         • **LTB4R2:** mediates chemotaxis of granulocytes and macrophages; inhibit chemotaxis; neuropeptide signaling pathway.
  Metabotropic GABA receptors        GABA~B2~ (GABBR2)   Gi and Go                                                                       **Ligand:** γ-Aminobutyric acid (GABA)
                                                                                                                                         • Involved in the fine tuning of inhibitory synaptic transmission; pre-synaptic GABA receptor is an inhibitory neurotransmitter in the brain; postsynaptic GABA receptor decreases neuronal excitability; involved hippocampal long-term potentiation, slow wave sleep, muscle relaxation and anti-nociception; gamma-aminobutyric acid signaling pathway.
  Metabotropic glutamate receptors   mGluR2 (GRM2)       Gi/Go                                                                           **Ligand:** Glutamate
                                     mGluR3 (GRM3)                                                                                       • **mGluR2:** may be involved in suppression of neurotransmission; may be involved in synaptogenesis or synaptic stabilization; chemical synaptic transmission; glutamate secretion; regulation of synaptic transmission, glutamatergic;
                                     mGluR4 (GRM4)                                                                                       • **mGluR3:** chemical synaptic transmission; regulation of synaptic transmission, glutamatergic;
                                                                                                                                         • **mGluR4:** may have a role in modulation of glutamate transmission in the CNS; chemical synaptic transmission; neurotransmitter secretion; regulation of neuronal apoptotic process; regulation of synaptic transmission, glutamatergic;
                                     mGluR6 (GRM6)                                                                                       • **mGluR6:** may have an important function in some inherited eye diseases; required for normal vision; chemical synaptic transmission; regulation of synaptic transmission, glutamatergic;
                                     mGluR7 (GRM7)                                                                                       • **mGluR7:** may have a role in modulation of glutamate transmission in the CNS; chemical synaptic transmission; negative regulation of glutamate secretion; regulation of synaptic transmission, glutamatergic; sensory perception of smell; sensory perception of sound; short-term memory; transmission of nerve impulse;
                                     mGluR8 (GRM8)                                                                                       • **mGluR8:** presynaptic receptor may modulate glutamate release at the axon terminals of mitral/tufted cells in the entorhinal cortex; regulation of synaptic transmission, glutamatergic.
  Oxytocin receptors^∗^              OT (OXTR)           Gi/Go but mainly Gq/11                                                          **Ligand:** Oxytocin
                                                                                                                                         • Stimulates contraction of uterine smooth muscle and of mammary gland; stimulates milk secretion in response to suckling; memory; positive regulation of synapse assembly, positive regulation of synaptic transmission, GABAergic and glutamatergic; positive regulation of norepinephrine secretion; sleep; social behavior.
  Adenosine receptors^∗^             A1 (ADORA1)         Gi/Go                                                                           **Ligand:** Adenosine
                                                                                                                                         • **A1:** distributed widely in peripheral tissues where they have a mainly inhibitory role; cognition; excitatory postsynaptic potential; negative regulation of long term synaptic depression; negative regulation of mucus secretion; negative regulation of neurotrophin production; negative regulation of synaptic transmission, GABAergic; negative regulation of synaptic transmission, glutamatergic; nervous system development; regulation of respiratory gaseous exchange by neurological system process;
                                                                                                                                         • **A3:** may play a role in reproduction.
                                                                                                                                         

∗

The protein levels of these receptors in the brain were not reported in the Human Protein Atlas. However, as these GPCRs are known to play important functions in the brain, and their protein levels decrease with age, they were also included in this analysis. Data was taken from UniProt (

The UniProt Consortium, 2017

) and InterPro (

Petryszak et al., 2016

) database and included brain related Gene Ontology (GO) annotations (Molecular functions and Biological processes). 'Gi and Go', GPCRs that couple with both Gi and Go proteins; 'Gi/Go', GPCRs known to couple with at least one of these Gα proteins (

Gimpl and Fahrenholz, 2001

;

Guo et al., 2001

;

Hunyady and Catt, 2006

;

Peres et al., 2007

;

Svízenská et al., 2008

;

Jiang and Bajpayee, 2009

;

McQuail et al., 2013

).

Age-Induced Alterations in Brain-Enriched G~i/o~- Coupled GPCRs
===============================================================

Age-related alterations in neurotransmitters, their receptors, and related neuromodulatory systems may affect the responsiveness of receptors to neurotransmitters, leading to abnormal signal transduction activity via the receptors themselves or via other GPCRs they associate with at the membrane. As such, alterations in GPCRs' expression and activity with aging can be associated to aging hallmarks and age-related pathologies. Decreased expression or activity of GPCRs and G proteins have indeed been associated to alterations in neuronal plasticity and increased sensitivity to neurodegenerative processes, with a consequent decline in cognitive, motor, and even sensory capabilities ([@B161]; [@B73]; [@B149]). These associations suggest a crucial role for GPCRs in aging and in age-related and protein aggregation-associated pathologies, such as Alzheimer's, Parkinson's, and Huntington's diseases, as well as vascular and frontotemporal dementia ([@B161]; [@B73]; [@B3]; [@B97]).

Alterations in the signaling pathways evoked by GPCRs can occur with age at various molecular levels, from ligand- or G protein-GPCR interactions to downstream intracellular signaling pathways involving the G~i/o~ effector proteins. Altered structure or functionality of the plasma membranes' lipids, and on the membrane fluidity by lipid peroxidation, can all induce changes in the GPCR's activity and density (number of molecules in a given region as a membranar nanodomain). In addition to the lipid environment, the loss of receptors can result from reduced protein synthesis and increased accumulation of aberrant non-functional proteins due to impaired proteostasis ([@B74]), and from cell degeneration and death due to trauma, toxins or pathologies ([@B99]; [@B47]; [@B3]) ([Figure 3](#F3){ref-type="fig"}).

![Main mechanisms of age-induced GPCRs decline. With aging, there is a general decrease in G~i/o~-coupled GPCRs protein levels throughout the brain. Though many elements are involved, there are three main factors: (1) alterations in the plasma membrane structure and fluidity caused by events like lipid peroxidation; these lead to the instability of membrane proteins, including GPCRS, and result either in their altered function or decreased levels and densities at, e.g., signaling nanodomains; (2) hindered proteostasis: decreased protein synthesis due to alterations in transcription factors or increased mRNA instability, and accumulation of aberrant GPCRs and other signaling proteins due to less efficient proteasome or autophagy (Aphg) quality control systems, may lead to a decrease in the levels of functional GPCRs in the aged brain; (3) the increased incidence of neurodegenerative diseases and physical trauma with aging, together with exposure to toxins, all lead to neuronal death. Moreover, the alterations in protein synthesis and membrane structure can eventually contribute to the onset or progression of neurodegenerative pathologies, with a subsequent further decrease in some GPCRs' levels.](fnagi-11-00089-g003){#F3}

A compilation of age-related alterations in the brain densities of relevant G~i/o~-coupled GPCRs and in their affinities to ligands or other compounds, can be found in [Supplementary Table S2](#SM2){ref-type="supplementary-material"}. Notwithstanding some contradictions, general lines could be taken from the compiled studies and are discussed below. A tendency can be observed for a general age-related decrease in the brain density of these GPCR receptors. In fact, the density of 64.3% of the studied G~i/o~-coupled receptors subtypes decreased with aging (corresponding to 44.1% of the density studies). GPCRs densities were observed to increase in only ∼10.5% of the studies, although corresponding to the other third of the analyzed GPCR subtypes (35.7%). Around 45.4% of the studies retrieved unaltered GPCR densities with advanced age. The affinity of the receptors to their ligands seems to not have suffered as much with age as their density. Indeed, 78% of the analyses to brain G~i/o~-coupled GPCRs affinities did not show alterations, ∼8.5% showed decreased affinity and 13.5% increased affinity to ligands. When both parameters (density and affinity) are combined in the 'Binding potential' of the GPCRs to their ligands, an age-related decrease of 50.6% is observed. Of note, the 'Binding potential,' which is calculated as the ratio between *B*~max~ (total density of the receptor) to *K*~D~ (the equilibrium dissociation constant of the tested radioligand), is thus a parameter that decreases when the receptor's density decreases or when it has a higher tendency to dissociate from its ligand, as for example a decrease binding to an agonist due to a lower level of pre-coupled association with a G protein in the resting state.

Age-associated changes vary not only between GPCRs classes and subtypes, but also depending on the specific brain region ([@B194]; [@B19]; [@B260]). These region-specific effects may be ascribed to the different rates of neuronal differentiation and maturation of the various brain regions ([@B233]), leading to different patterns and rates of receptors' biosynthesis and maturation after birth, besides the differential sensitivity to external and internal hazard ([@B83]; [@B8]). Specific information on age-related alterations of each GPCR class and subtype is presented below.

Adrenoceptors
-------------

Age-associated changes in the densities of various adrenoceptors vary with the subtype of receptor to the brain area and specific layer ([@B19]). With age, the density of adrenoceptors particularly decreases in the striatum and various cortical regions (frontal, temporal, primary visual, prefrontal, motor, and somatosensory cortices) ([@B180]) ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}). The levels of α2-adrenoceptor may decrease with age due to the known loss of presynaptic noradrenergic terminals in layer I ([@B194]; [@B19]). This reduction can have important functional consequences in synaptic integration of inputs originated from different cerebral regions ([@B43]), contributing to the motor and somatosensory deficits observed in elderly individuals. Alterations in the brain adrenergic system with advanced age seem to correlate with increased depression and memory loss incidence ([@B9]; [@B168]).

Abnormal CNS adrenergic activity has also been suggested in patients with Alzheimer's disease (AD), with a decrease in the α2-adrenoceptor density being observed in AD patients' brains ([@B156]).

Dopamine Receptors
------------------

The dopaminergic system modulates neurotransmission in areas known for their vulnerability to aging, as the substantia nigra and striatum (areas related to movement control and affected in Parkinson's disease, PD) and the hippocampus, a region with a role in learning and memory (affected in AD) ([@B111]; [@B5]).

Age-related decline in the dopaminergic neurotransmission (including decreased protein and mRNA levels of the D2 receptors and their binding potential) has been observed in various species, such as rabbits, rats and humans, and is one of the more consistent manifestations of neural aging and age-related degeneration ([@B248]; [@B182]; [@B271]; [@B90]; [@B110]; [@B124]; [@B169]; [@B222]; [@B49]; [@B161]; [@B268]; [@B7];[@B214]; [@B257]; [@B266]; [@B212]; [@B111]; [@B103]; [@B262]; [@B151]; [@B48]) ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}). The decline of dopamine receptors with aging might be a direct effect of the loss of dopaminergic and their target neurons in the aging brain and/or the expression of autoreceptors on dopamine neurons ([@B173]; [@B25]; [@B48]). Indeed, cells in the substantia nigra project to the striatum with a regionally corresponding arrangement, and the observed reduction in dopamine receptors may also result from cortical and thalamic atrophy, and loss of striatal size with age ([@B170]; [@B111]; [@B208]). Further, the decline in dopamine receptors also results from their reduced biosynthesis and incorporation into the neuronal membranes, partially due to decreased transcription in surviving dopaminergic neurons or increased receptor degradation ([@B169]; [@B213]; [@B85]; [@B161]; [@B7]; [@B257]). As such, age-related decrease of D2 receptor in striatum and neuronal cell loss in the substantia nigra have been associated to a decline in the synaptic dopamine reuptake due to age-related decline of the dopamine transporter (DAT) in the striatum ([@B104]). Regarding gender, [@B202] reported gender-related differences in D2 receptor affinity in the left striatum with age, which may contribute to the differential vulnerability of men and women to psychiatric disorders like schizophrenia ([@B202]). In contrast to D2, the D3 receptor levels were shown to increase with age in the striatum and nucleus accumbens, which might represent increased D3 receptor function in these regions to compensate D2 receptor striatal loss ([@B265]). It is still controversial if D3 receptor levels change in the aged human substantia nigra, since \[^11^C\]-(+)-PHNO binding to D3 receptor was found either unaltered or increased ([@B172]; [@B151]). Alterations in the D4 receptor with age have been by far less studied ([@B257]); however, it would be interesting to understand if age-associated circadian rhythm alterations are associated with altered D4 levels or their heterodimerization with adrenergic receptors (α~1~B and β~1~), with consequent mis-regulation of adrenergic receptor-induced melatonin synthesis ([@B72]). As dopamine neurons are associated with motor, cognitive and endocrine functions, the loss of dopamine neurons and receptors with age most likely contributes to age-related decreased frontal metabolism, cognitive and memory performances, and decreased motor functions ([@B161]; [@B257]). Indeed, the dopaminergic network seems to be intimately associated with the senescence process. Most D2 dopamine receptors in the CNS are coupled to the G~o~ protein, with the usually robust ability of GTP to regulate the binding affinity of dopamine to D2 receptors being absent in G~o~-deficient mice ([@B108]).

In agreement to its tight relation with aging, alterations in dopamine receptors are also characteristic of age-related pathologies as PD, but also of other disorders, such as Gilles de La Tourette's syndrome, depression, schizophrenia, and attention deficit disorder ([@B160]; [@B206]; [@B48]; [@B205]).

Acetylcholine Receptors
-----------------------

Acetylcholine (ACh) receptors play an essential role in neural network support, with their levels peaking very early (at 3 months of age) in the rat hippocampus ([@B251]). Different subtypes of ACh receptors appear to have different sensitivities to aging, with mRNA and protein levels of the muscarinic M2 receptor suffering a more pronounced age-induced decrease than the ones of the M4 receptors. Nevertheless, alterations in other subtypes of muscarinic receptors may not be as relevant as for M2. For example, significant changes in the density of the M1, M3, and M4 receptor subtypes were detected in the cerebellum but probably have a minimal impact on cerebellar function since over 90% of the cerebellum muscarinic receptors belong to the M2 subtype ([@B23]; [@B181]; [@B129]; [@B251]) ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}).

The age-related decrease in the M2 densities at the hippocampus and frontal cortex may affect processes such as learning and memory and other cognitive functions ([@B251]; [@B220]) ([Table 1](#T1){ref-type="table"}). [@B177] reported that normal, healthy aged rats have an age-related increase in cognitive rigidity associated with reduced muscarinic receptor function in the dorsomedial striatum, even if there is no visible loss of M2/M4 receptor densities ([@B177]).

Age-related loss of ACh receptors or impairment of their function could also be implicated in the pathophysiology of age-associated CNS diseases, such as Parkinson's and Alzheimer's diseases ([@B245], [@B246]; [@B199]). However, activation of M2 and M4 mAChRs receptors aggravated the formation of the amyloid-β peptide and inhibited the release of the neurotrophic sAPPα peptide, potentiating AD ([@B249]).

Serotonin Receptors
-------------------

Limbic and neuroendocrine control areas are under the influence of serotonergic innervation ([@B10]) and the effect of aging on the serotonergic signaling has been thoroughly studied ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}).

Cognitive deficits ([@B10]), changes in sleep ([@B10]; [@B158]), food intake ([@B10]; [@B158]), mood ([@B10]), circadian rhythms, neuroendocrine function, affective state, memory and hormone secretion ([@B159]; [@B130]), and decreased libido ([@B10]) are some of the disturbances that have been attributed to age-related changes in the serotonergic system ([@B150]). Age-dependent decreases in 5-HT1-receptor binding potential (mainly resulting from alterations in the 5-HT1A subtype, see [Supplementary Table S2](#SM2){ref-type="supplementary-material"}) occur in the hypothalamus, in various cortical regions including the frontal cortex, and in the hippocampus and brainstem (these both only significantly in men) ([@B158]; [@B244]; [@B193]; [@B150]). In the frontal cortex, there is a decrease in the receptor's affinity ([@B19]), as well as a decrease in G protein activation induced by a 5-HT1A agonist ([@B73]), revealing this region as being highly affected by age. Contrarily, an increase in 5-HT receptor binding potential was observed at basal ganglia (putamen, pallidum) ([@B150]) and enhanced downstream G protein signaling at the hippocampus ([@B57]). Indeed, although the 5-HT1A receptor density decreased in the aging hippocampal CA1 region ([@B28]), 5-HT1A receptor-stimulated \[^35^S\]GTPγS binding increased, representing a compensatory mechanism at this region; this is not observed, e.g., in the dentate gyrus, in spite of it also presenting decreased 5-HT1A density ([@B57]). Gender-specific age-related decreases in 5-HT1A binding potential ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}) were hypothesized to result from differences in hormonal levels and distribution, as of circulating estrogen ([@B158]). Reduction in 5-HT1 receptor density with aging may result from decreased receptor synthesis ([@B189]), loss of neuronal cell bodies ([@B52]) and/or alterations in the lipid environment of neuronal cell membranes, namely increase in viscosity and reduction in fluidity due to lipid peroxidation ([@B52]; [@B99]; [@B189]).

Pathological alterations of the 5-HT metabolism and/or loss of serotonergic neurotransmission can also lead to several CNS pathologies, including AD, schizophrenia, depression, and anxiety. Serotonergic systems represent a potential therapeutic target for the treatment of AD, since decreased serotonergic neurons and/or reduction of serotonergic projections can be observed in AD patients ([@B30]). Further, 5-HT1A receptor levels were reported to be decreased in the hippocampus and frontal cortex of AD patients ([@B166]; [@B261]). At a molecular level, altered serotonin signaling seem to have a role in the production of toxic amyloid proteins and amyloid plaques, leading to the progression of the disease ([@B30]). Relatively to PD, a decrease in the 5-HT1A binding potential has been detected in the midbrain raphe of PD patients, correlating with the severity of tremors ([@B54]). In parallel, the density of these receptors was observed to be increased in the temporal cortex of patients with PD and Lewy body dementia experiencing depression ([@B225]; [@B79]).

Opioid Receptors
----------------

The opioid system is involved in the modulation of several physiological processes, such as analgesia, stress response, immune response, synaptic activation and neuroendocrine function ([@B279]). For example, kappa (κ) receptors are located on presynaptic axonal terminals, modulating the release of other classes of neurotransmitters, such as acetylcholine and substance P ([@B240]). Further, opioids induce modifications in the endocrine system resulting in stimulatory or inhibitory effects on hormone release ([@B264]). With advanced age, the capacity of opioids to regulate hormones of the pituitary gland is decreased, and it is suggested that receptor expression could depend on the endocrine environment ([@B36]).

Age-related decreased densities of opioid receptors have been observed at the striatum, frontal poles, anterior cortex, hippocampus ([@B91]; [@B200]; [@B143]) ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}). The kappa receptors are the main affected ones, being particularly decreased at the substantia nigra, striatum (caudate and putamen) and various cortical regions including the lateral agranular field of frontal cortex. The potency of an antagonist of kappa receptors was also found decreased in the medial pre-frontal cortex ([@B230]). The decreased opioid binding to kappa receptors may result from age-related destruction of cell bodies and consequent degeneration of axons ([@B92]). On the other hand, opioid signaling via the mu (μ) receptor seems to increase with age at the prefrontal cortex, but its density is decreased at the hypothalamus ([@B73]).

The functions of the opioid system in learning and memory ([@B249]; [@B279]) support a possible linkage between the opioid system and Alzheimer's disease ([@B148]), which is also reinforced by the overlap between the distribution of opioid receptors and the localization of the amyloid plaques in AD patients ([@B279]). Other links include the fact that opioids can modulate the release of acetylcholine and substance P, already associated with AD ([@B17]). Furthermore, the agonist-induced activation of the human delta (δ) opioid receptor increases the activities of β- and γ-secretase, which leads to the increased production of the amyloid-β peptide ([@B219]).

Somatostatin Receptors
----------------------

Somatostatin systems are highly expressed in the mammalian brain and are involved in many brain functions such as motor activity, sleep, and sensory and cognitive processes ([@B36]). Somatostatin receptors (SSTRs) are also involved in some pathologies, such as Alzheimer's disease, neuroendocrine dysfunctions and several types of cancer (mainly the SSTR2 subtype in the case of human tumors) ([@B195]).

Down-regulation of somatostatin receptors was observed in normal aging ([@B122]; [@B68]), and their affinity to ligands decreases with age at hippocampus, striatum and frontal cortex ([@B231]; [@B209]; [@B226]) ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}). Importantly, in contrast to rodents, human SSTRs maintain their density in the cerebellum ([@B71]; [@B125]), suggesting that somatostatin plays an important role in the mature human cerebellum ([@B125]).

A decline of somatostatin receptors (possibly SSTR2 and SSTR4) was also observed in AD brains, and is related to the degree of dementia ([@B122]; [@B68]). Indeed, a decline in these receptors was observed to lead to reduced action of neprilysin, an enzyme that degrades the amyloid-β peptide, leading to the accumulation of amyloid-β in AD senile plaques. As such, somatostatin receptors are potential pharmacological targets for prevention and treatment of AD ([@B27]).

Angiotensin Receptors
---------------------

Angiotensin II, a ligand of angiotensin type 1 (AT1) receptors, is known to be an inducer of inflammation and oxidative stress ([@B263], [@B262]; [@B105]).

[@B18] have observed that mice lacking AT1 receptors have higher longevity due to their lower oxidative stress, and have increased protection against age-related progression of atherosclerosis ([@B18]).

In fact, the inhibition of the AT1 receptor has been suggested to aid in the attenuation of several cognitive pathologies ([@B105]). Increased activity of the local renin-angiotensin system (RAS), via an increased expression of AT1 receptors in substantia nigra, seems to be involved in age-related loss of dopaminergic neurons and in an increased risk for PD due to the upregulation of NADPH-dependent oxidases ([@B263], [@B262]; [@B105]). Further, inhibition of AT1 receptors in aged rats led to a decrease in their higher susceptibility to dopaminergic neurotoxins ([@B263], [@B262]).

Cannabinoid Receptors
---------------------

The cannabinoid system modulates multiple physiological processes, mainly in the central motor system, being involved in learning, memory, motor and reward processes, regulation of pain mechanisms and protection against neuroinflammation ([@B260]; [@B201]; [@B237]).

Loss of cannabinoid 1 (CB1) receptors can result in neuronal loss and cognitive deficits characteristic of the aging brain ([@B201]; [@B237]). With advanced age, CB receptors decrease and undergo biochemical and functional alterations in various cortical areas and in extrapyramidal structures ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}). In the latter, selective degeneration of neurons with CB receptors, and a reduction in receptor synthesis involving a decline of mRNA levels, are possible mechanisms leading to the visible CB receptor loss ([@B144]; [@B217]; [@B149]). The CB receptors also have their signaling through G proteins decreased at substantia nigra and frontal cortex ([@B217]; [@B149]). These alterations are possibly implicated in the pathophysiology of distinct neurological and psychiatric disorders, such as PD, Huntington's chorea, AD, schizophrenia and depression ([@B217]; [@B101]; [@B149]; [@B260]; [@B270]; [@B242]), with these receptors being considered a new target for drug treatment of neuropsychiatric disorders. At a molecular level, lack of CB1 receptors are suggested to influence the course of brain aging via induction of lipofuscin accumulation, reduced expression and activity of cathepsin D, and alterations in lysosomal protease activity with subsequent decreased degradation of damaged macromolecules in the hippocampus ([@B201]). Regarding the binding potential, gender- and region-dependent increases in the CB1 receptor binding were detected in the human memory, limbic and motor circuits ([@B260]). The authors hypothesize that these alterations may reflect a way to compensate age-related endocannabinoid dysfunction (decreased ligand levels at, e.g., the hippocampus), functional losses in other monoamine systems, or may even result from increased expression of the receptors in non-neuronal elements such as glial cells. Gender-dependent CB1R up-regulation can result, e.g., from compensatory mechanisms modulated by sex hormones ([@B260]). In mouse hippocampus (and parieto-temporal cortex), an increase in \[18F\]FMPEP-D2 binding is observed during aging, which could be a compensatory reaction against to the age-related endocannabinoid dysfunction that has been described in rodents ([@B142]; [@B32]; [@B242]).

The mRNA levels of CB1R were found to be significantly decreased in the brains of patients with Parkinson's disease, specifically in the striatum (caudate nucleus and putamen) and globus pallidus ([@B101]). These alterations not only indicate a connection between changes in the dopaminergic system and the cannabinoid system, but also reinforce the cannabinoid receptors as potential targets in the treatment of PD.

Metabotropic GABA Receptors
---------------------------

GABA is the main inhibitory neurotransmitter, being involved in a plethora of brain regulatory mechanisms ([@B197]; [@B117]).

As our brain gets older, the density of GABA receptors particularly decreases in the frontal cortex ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}). Age-induced decreased GABAergic signaling can have as consequence loss of memory and impaired cognitive abilities, related to both medial temporal lobe and frontal cortical systems ([@B154]). These are brain regions particularly vulnerable to aging alterations, and aged rodents present frontal cortical dysfunction that causes loss of behavioral flexibility ([@B16]; [@B221]; [@B216]; [@B154]). In humans, the protein density of GABA~B~R2 was found decreased in the frontal cortex ([@B154]), while unaltered in the cerebellum, temporal gyrus, hippocampus, sensory and motor cortices ([@B154]; [@B190]). In addition, activation of the GABAergic signaling via downstream G proteins is also decreased with age at the prefrontal cortex ([@B73]). Decreased GABAergic signaling may reflect a decrease in the GABA receptors-containing nerve terminals at specific brain regions, or be a consequence of peripheral loss of input ([@B164]; [@B37]). It may also relate to decreased function of its downstream G~i/o~ protein signaling (discussed later on). A recent study reported an age-related increase in the mRNA levels of several GABA receptors in the primary visual cortex of rhesus monkeys, suggested to be a compensatory feedback mechanism for the reduced release of GABA found in this region ([@B135]).

In age-related Alzheimer's pathology, GABAergic neurotransmission undergoes a dynamic remodeling. Astrocytes in AD brains were observed to have up-regulated GABA release, which binds to extrasynaptic GABA receptors and inhibits synaptic function, causing memory and cognitive deficits ([@B109]). In this sense, GABA receptors may be promising therapeutic targets for AD, using antagonists to alleviate the inhibition of synaptic function and improve cognition ([@B134]).

Metabotropic Glutamate Receptors
--------------------------------

Glutamate is considered the major excitatory neurotransmitter in the mammalian brain ([@B96]; [@B26]), being implicated in diverse CNS signaling pathways, mediating neuronal excitability, synaptic plasticity and neurotransmitters' release ([@B61]; [@B26]; [@B280]).

With aging there is an excessive glutamate release ([@B66]), and increased glutamate-mediated excitotoxicity has been widely reported in age-related diseases ([@B218]). Regarding its receptors, there is an age-dependent increase in protein and mRNA levels of group II mGlu receptor proteins (mGluR2 and mGluR3). This occurs in various brain regions ([@B6]), including the frontal cortex, striatum (caudate and putamen), thalamus, cerebellum, and the hippocampus ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}). mGluR2/3 increased levels can result from increased synthesis of receptors to compensate the excessive release of glutamate with aging ([@B229]). Contrarily, mGluR7 mRNA levels decrease with age in various brain regions, and may contribute to the age-related decline in sensory functions ([@B228]).

Metabotropic glutamate receptors are extensively reported to be involved in Alzheimer's disease. For example, down-regulation of group II mGluR signaling through the use of antagonists may be a therapeutic approach for AD, since these receptors stimulate the release of amyloid β42, the predominant isoform of the amyloid-β peptide accumulated in AD brains. However, group II mGluRs agonists have shown to be neuroprotective against amyloid β toxicity ([@B249]; [@B33]). Further, in the striatum and thalamus, agonists of group III mGluR proteins (mGluR4, mGluR6, mGluR7, and mGluR8) have an inhibitory effect on glutamate release, and may counteract excitotoxic neurodegeneration associated with age-related pathologies ([@B218]; [@B229]). In this sense, activation of group III mGluRs has been established to be neuroprotective ([@B211]; [@B33]). Besides AD, these receptors are also implied in other neurodegenerative diseases such as Parkinson's and Huntington's diseases ([@B211]).

The protein levels of the following two G~i/o~-coupled GPCRs are not available at the Human Protein Atlas database, but their mRNA levels are quite abundant in brain. Further, they are known to play important functions in the brain, and their protein levels change with age. Hence, they were subsequently included in this section.

Adenosine Receptors
-------------------

Adenosine receptors are involved in the modulation of several brain functions, such as cognition, neurodevelopment and the sleep-awake cycle ([@B29]; [@B39]; [@B98]).

With aging, a reduction in the turnover rate of adenosine receptors ([@B64]) and a decline in the functional output of the adenosine A1 receptor pathway ([@B157]) have been observed. Reduction in the A1 receptor binding may be related to a specific reduction in A1 receptor's levels ([@B187]; [@B234]; [@B163]), a specific neuronal loss, or alterations of the neuronal set-up of A1 receptors, since there is a replacement of neuronal cells by glial cells ([@B187]; [@B47]). It may also result from a modification of the lipid environment of the receptor due to membrane peroxidation, or by alterations in adenosine receptors' mRNAs due to a decreased transcription of the receptor gene and/or a decrease in its mRNA stability ([@B47]; [@B41]). These changes can have implications in the plasticity and function of the brain, and be associated to ischemia/hypoxia, dementia, and AD ([@B60]; [@B157]; [@B163]).

Regarding the AD pathology, a significant increase in A1 receptors was observed in degenerating neurons presenting neurofibrillary tangles, and in dystrophic neurites of senile plaques in the hippocampus and frontal cortex of AD patients ([@B6]; [@B2]).

Oxytocin Receptors
------------------

Oxytocin (OT) receptors are present in the CNS, with oxytocinergic neurons presenting widespread projections and modulating synaptic transmission and network activity in the hippocampus ([@B11]; [@B145]).

Age-related reduction in OT binding was reported in the caudate putamen, the olfactory tubercle, and the ventromedial hypothalamic nucleus of 20-month old rats. These reductions were due to a decrease in the binding area rather than from a decrease of the binding density within each area ([@B11]). The authors also hypothesized a link between this reduction in binding and a reduction in steroid hormones, such as testosterone, detected in the aged animals. This could be especially true for the olfactory tubercle and the ventromedial hypothalamic nucleus, since previous studies showed a modulatory effect of steroid hormones on the expression of OT receptors in these areas ([@B253]). Supporting this idea, a study showed that there were no significant alterations in OT ligand binding in 'steroid-independent' regions, such as the anterior olfactory nucleus, the dorsal peduncular nucleus and the ventral subiculum. However, this correlation between steroid action and OT binding did not apply to all areas of the brain. In the bed nucleus of stria terminalis and central amygdaloid nucleus, there were no alterations in binding despite the sensitivity of these areas to gonadal steroids. The loss of striatal OT receptors might also be due to neuronal cell death, to a decrease in the striatal dopamine content and of dopamine D2 receptors, since a stimulatory effect on the secretion of OT has been suggested for dopamine in some reproduction-related situations ([@B11]).

An analysis of the receptors discussed in this section indicates that, during the aging process, there is mainly a reduction in G~i/o~-coupled GPCR densities in particular brain areas (further summarized in Section "Conclusion"). This reduction most probably results from peroxidation of the membrane, imbalanced proteostasis (reduced biosynthetic capacity and impaired protein quality control), and neuronal degeneration and death ([Figure 3](#F3){ref-type="fig"}). Additional insight on how these systems changes with age can be gathered by taking into account the extent of the area affected with aging and the differentially availability of the GPCRs in the brain ([@B48]). Regarding receptors' affinities, although most of the studies reported no alterations, around 8.6% of GPCRs showed decreased binding potential.

Besides alterations resulting from the normal aging of the brain, altered GPCR signaling strongly correlates with the development of age-associated and other neuropathologies ([@B97]). In Alzheimer's disease brains there is a decline in the densities and/or function of, e.g., α2-adrenoceptor ([@B156]), acetylcholine ([@B245], [@B246]), 5-HT1A serotonin ([@B166]; [@B30]; [@B261]), and somatostatin receptors ([@B122]; [@B68]), but an increase in adenosine A1 receptors ([@B2]). Decreased serotonin, glutamate, somatostatin, adenosine, and opioid receptors/transmission have all been associated with changes in cognitive and/or memory functions and with AD and the degree of dementia, together with increased metabotropic glutamate (group II mGluR) and extrasynaptic GABA signaling ([@B148]; [@B122]; [@B2]; [@B68]; [@B249]; [@B109]; [@B219]; [@B30]; [@B134]; [@B87]; [@B33]). In Parkinson's disease, the levels, binding potential and/or function of GPCR receptors for dopamine ([@B160]; [@B206]; [@B48]), acetylcholine ([@B245], [@B246]; [@B199]) and serotonin ([@B54]) were found decreased. Further, declines in the levels of dopamine ([@B206]; [@B79]), serotonin ([@B54]; [@B225]), acetylcholine ([@B199]; [@B246]), mGluR group III glutamate ([@B211]) and cannabinoid receptors ([@B101]) have been implicated in PD progression and symptoms, as well as increased signaling via angiotensin and mGluR group II metabotropic glutamate receptors ([@B263], [@B262]; [@B211]; [@B105]). Recent detailed information on the relation between GPCRs and neuropathologies can be found in [@B79], [@B97], and [@B140].

Degradation of specific G~i/o~-coupled GPCR signaling with aging and age-associated diseases may not only derive from the decreased levels of that specific GPCR, but also of other molecular players influencing the signaling mechanism, including the main ligand, membranar lipids and other GPCR interactors at the plasma membrane. These may include other GPCRs with which the GPCR in question dimerizes/oligomerizes (see below), regulators (e.g., GIT2, β-arrestin, allosteric regulators) ([@B40]; [@B51]; [@B58]; [@B259]), molecules of the signal transduction machinery including the G~i/o~ transducers and the AC effector ([@B120]), all composing a functional receptorsome. Recent studies show that many GPCRs (including dopamine D~1-3~R, serotonin 5HT, angiotensin AT~1~R, purinoreceptor P2YR, cannabinoid CB~1~, adrenergic β~2~AR, etc.) form functional homo- and heterodimers to successfully translate extracellular signals ([@B63]; [@B178]; [@B205]; [@B58]; [@B252]). Alterations in the assembly of the GPCR receptorsome complexes can alter the affinity to certain ligands, lead to desensitization or disruption of the signaling mechanism, potentially explaining the decreased binding potential and altered signaling detected in age-related studies, including specific deregulations of GPCR signaling in age-associated diseases ([@B77]; [@B62]; [@B205]; [@B58]; [@B146]).

These new mechanisms comprising GPCRs dimerization and association with other signaling molecules reveal that GPCRs are not single pharmacological entities and explain why alterations in the plasma membrane, associated to aging and its diseases, affect the efficacy of drugs targeting GPCRs ([@B51]). Further, due to this oligomerization and cooperative character, one may alter GPCR signaling by targeting other components of the receptorsome ([@B178]; [@B58]), including other GPCRs. For example, the targeting of the AT~1~R angiotensin receptor, a signaling hub of receptor crosstalk whose levels are increased in areas mainly affected by age, is expected to aid in the recovery of signaling from other GPCRs with which it dimerizes ([@B252]). The new knowledge on GPCR dynamics is thus a driving force in the research and development of new therapeutic drugs for age-associated diseases, from neurodegenerative to cardiovascular diseases, osteoporosis, type 2 diabetes mellitus, etc. ([@B79]; [@B97]; [@B140]; [@B252]; [@B259]; [@B31]; [@B146]). To achieve this goal it is necessary to understand how aging and age-associated disease impact other receptorsome components such as the downstream heterotrimeric G proteins.

G~i/o~ in Brain Development and Aging
=====================================

With age, the signaling downstream several G~i/o~-coupled GPCRs is altered, and may also be ascribed to alterations in their heterotrimeric G protein transducer. The alterations that these proteins suffer during brain development and aging are presented here, with a particular focus on G~αo~, the most abundant G~α~ subunit in the brain.

Regarding postnatal development, the brain mRNA levels of G~αo~ and G~αi~ were found to be slightly higher at P1 than in adulthood ([@B56]). G~αo~ and G~αi~ mRNA levels increased during the first 7 days postnatally and then decreased until P25 to levels equal to the adult brain. G~αs~ and G~β~ (the other G~α~ subunits analyzed) followed a similar pattern ([@B56]). Of note, this study did not specify the age of adult rats, and the characterization of a rat as "adult" or in 'early adulthood' can be based in a large window of ages (P21 to P92) ([@B152]; [@B223]). There is some discrepancy between these mRNA results and previous studies focusing on the G~αo~ protein levels during this phase of development. In these, G~αo~ protein levels were low at P1 and drastically increased during the first weeks of development until around day 25, where they achieved adult levels ([@B13]; [@B38]). The differences could result from a lag in the processing of the G~αo~ mRNA that affects the detection of the G~αo~ protein early in development ([@B56]). On the other hand, they could be due to alterations in the rate of G~αo~ protein turnover during development, with G~αo~ exhibiting a higher turnover rate at early stages of development, and a slower and more stable turnover as the brain matures. This second hypothesis was corroborated by follow up results demonstrating a slower G~αo~ protein turnover with neuronal differentiation ([@B24]). Later studies also showed brain region-specificities of G~αo~ levels. In rat cortex and thalamus, the protein levels of G~αo1~ (isoform 1 of G~αo~) slightly rise on the first postnatal days and then stabilize until adulthood (P90), while in the pituitary gland and in hippocampus, G~αo1~ levels significantly rise on the first 10--20 days and then start to slowly decrease until P90 ([@B102]).

The immunoreactivity of G proteins in the human brain has also been assessed in post-mortem brains of human individuals with ages ranging from 3 days to 92 years ([@B276]). In the whole brain, G~αi~ and G~αs~ (52 kDa form) immunoreactivities were observed to significantly decrease with age. G~αo~ also showed a tendency to decrease with age, although not statistically significant. G~β~ immunoreactivity presented no alterations with age, while G~αs~ (45 kDa form) tended to increase. Specific evaluation of G~αo~ in the pre-frontal cortex of human post-mortem brains, however, revealed a more significant correlation between aging and decreased G~αo~ immunoreactivity ([@B133]). Interestingly, neither G~αi~ nor G~αs~ exhibited major alterations with aging in this brain area. Of note, the differences between both studies can result not only from the different brain region analyzed, but also from some interindividual variability in the studied samples ([@B133]). A later study showed a decrease in both G~αo~ (slight) and G~αi~ (significant) levels in the pre-frontal cortex with aging ([@B73]), with the differential results between studies potentially residing in the range of ages represented in each study. While the [@B276] and [@B73] studies used samples from individuals with ages ranging from 3 days to 92-years-old and 1 to 88-years-old, respectively, the [@B133] study used samples from individuals with ages ranging from 19 to 100-years-old ([@B276]; [@B133]; [@B73]). The lack of samples from younger individuals in the [@B133] study and/or its older individuals might explain the absence of alterations in G~αi~ levels, as well as the detection of a significant decrease in G~αo~ levels.

The [@B133] study also compared control individuals to individuals with Alzheimer's Disease (AD), but no significant differences were detected in G proteins levels besides a slight decrease in G~αi1~ ([@B133]). These results are in accordance with previous works that also showed no alterations in G~αo~ levels in different regions of AD's brains ([@B153]; [@B186]), with more recent studies also confirming these results ([@B86]). Despite the lack of significant changes in G~αo~ levels in AD brains, G~αo~ signaling was found deregulated in AD patients. Forms of amyloid precursor protein (APP) with familial AD (FAD)-associated V642 mutations, such as V642 to I (London FAD mutation), F (Indiana FAD mutation) and to G (no FAD associated), have an increased capability to activate G~αo~, with this activation resulting in apoptosis and associated DNA fragmentation ([@B185]; [@B273],[@B274]). APP has also been shown to induce cell death via a mechanism involving both G~αo~ and Src activation ([@B239]; [@B272]). There are also some reports studying a possible link between G~αo~ and the Alzheimer's amyloid-β peptide (Aβ), with mixed results. While some reports show that Aβ does not participate in the APP-G~αo~ induced neuronal death ([@B238]), others demonstrated that Aβ toxicity in neuronal cells is dependent on APP binding to G~αo~ (via deletion studies of the G~αo~ binding sequence) and G~αo~ activity (via cells exposure to the G~αo~ inhibitor pertussis toxin, PTX) ([@B224]; [@B232]). These differences might be due to the different experimental setups. The Xu study intended to evaluate if Aβ mediated the neurotoxic effect of APP upon its "activation" with specific antibodies, thus placing Aβ downstream of APP G~αo~ interaction, while the Sola Vigo and Shaked studies placed Aβ upstream the APP-G~αo~ interaction.

G~αo~ alterations have also been associated with other neurological disorders. Although not age-related, these highlight the role of G~αo~ in the brain. Briefly, the levels of Go in its trimeric form are increased in Bipolar Affective Disorder brains when compared to control individuals ([@B67]); both G~αo~ mRNA and protein levels are decreased in the prefrontal cortex of adult suicide victims, while in teenagers the G~αo~ decrease is only detected in subjects with a history of mental illness ([@B59]).

Taking together, these studies indicate that G~αo~ expression in the human brain changes during brain development and aging, and that these alterations vary between different brain regions. Moreover, while alterations in G~αo~ levels do not seem to be associated with AD, a deregulation of G~αo~ signaling might play an important role in this age-related disease.

Considerations on Age-Related Studies on GPCRs and Coupled G Proteins
=====================================================================

Although the studies here analyzed were generally consistent in relation to an age-induced decreased in various GPCRs densities, some studies reported no alterations or even an increase in the same receptors' densities. Differences between studies may be related to the specific brain region studied (already addressed in our approach to the GPCRs and G proteins studies), experimental methodologies used, differences in species/strains/individuals, age and gender/sex of the studied individuals.

Regarding the methodologies, several studies used ligands that have different affinities for the receptors; further, these ligands were sometimes non-selective or only slightly selective to the subtype of GPCR ([@B10]; [@B111]; [@B247], [@B245]; [@B151]; [@B128]; [@B242]). Radioisotope ligand-binding assays may also present some limitations. For example, the most used isotope, ^3^H, emits β-particles of low energy that are differently absorbed by tissues ([@B136]). By its turn ^125^I emits high energy particles that reduce the method's resolution ([@B136]; [@B85]). The receptors' levels were also analyzed by different techniques. The GPCRs' mRNA was assessed by Northern blot, or by the highly sensitive polymerase chain reaction (qPCR) technique, useful when only small amounts of tissue are available and when the target transcript is of low abundance ([@B28]). Importantly, mRNA levels not always coincide with protein ones; as proteins are the GPCRs functional molecules, we have here placed a main focus on GPCRs' protein levels ([@B228]; [@B277]). Studies in *postmortem* tissues also have some restrictions since delays and the freezing storage process (temperature and tissue storage duration) may alter the integrity of receptors' mRNA and protein ([@B149]).

Additionally, changes in the aging brain may vary between species, strains and even individuals ([@B215]; [@B60]; [@B277]). Studies have shown that humans and rhesus macaques have diverged from mice due to a marked increase in age-dependent down-regulation of neuronal genes' expression ([@B139]). This is an evolved feature of the human (and macaque) aging brain that might alter neural network and contribute to age-related cognitive changes ([@B139]). Despite common neurodevelopmental processes in mammals, only a small subset of age-related alterations in gene expression are conserved from mouse to man ([@B139]). In this way, experimental animals cannot fully model human, with the evolutionary distance between species being a limitation in scientific research ([@B139]; [@B227]). On the other hand, morphological changes in the aging brain also depend on the age of individuals ([@B60]). Studies of the biology of the aging brain using comparative survival curves for humans, mice, and rhesus monkey, suggest that a 30-month-old mouse is similar to an 81-year-old human and a 30-year-old rhesus monkey is similar to a 70-year-old human ([@B139]). So, some contradictory reported results may be ascribed to differences in the age of the animals used, and possibly some age-related alterations might have been underestimated due to such differences. Also, it is important to consider sample size, as lower values will translate into low statistical power and can cause discrepancies in studies. In techniques such as molecular imaging, this is probably due to its high monetary cost and to the desire to limit radiation exposure in healthy volunteers ([@B113]; [@B242]).

A clear comprehension on how gender/sex and age affect (neuro)pathologies is very important, and these two factors should be included as selection criteria or experimental parameters in the design and interpretation of this type of studies ([@B190]). Regarding age, many studies have used only 'under-aged' subjects, such as rats and mice aged 24 months or even less \[e.g., the oldest mice used in [@B275] study were 12-months-old\], or human individuals with ages ranging, e.g., from 22 to 53 years old ([@B133]; [@B244]; [@B275]). In many studies, statistical significance was only obtained in 30-month-old rats but not in 24-month-old rats, which may justify contradictory results ([@B163]). Gender/sex can also influence the density and affinity of GPCRs. Indeed, it appears to exist a gender/sex influence on the control of the aging mechanisms, and in the structure and function of the CNS, including in the synaptic alterations with aging and age-related pathologies ([@B162]; [@B189]). Some studies have addressed and revealed these gender/sex-specific alterations in GPCRs levels and function in animals and human samples ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}).

It is thus important in the future to pay attention to these variables, and increase the number of human studies covering a good age interval and differentiating between both genders, in order to minimize discrepancies in results and make it easier to draw reliable conclusions on age-related GPCRs alterations in the human brain.

Conclusion
==========

This review shows that the main age-related hallmark of G~i/o~-coupled GPCRs is their decreased brain densities (and associated binding potential), found in roughly two thirds of the subtypes of receptors studied. This may result in loss of function, particularly in brain regions where decreased density is associated with altered binding/agonist association, and/or decreased G protein levels or downstream signaling. Further, due to formation of GPCR dimers at the membrane, the decreased density of a GPCR may strongly affect the efficiency and the signaling pathway of another GPCR (and the pharmacological treatment to be applied). Some brain regions are more affected than others, including (1) the cortex, particularly the frontal cortex but also the temporal and other cortex lobes, (2) the striatum (caudate, putamen, nucleus accumbens), (3) substantia nigra, and (4) the hippocampus. These brain regions particularly sensitive to aging are related to functions such as learning, planning and execution, memory, and motor control. Homeostatic functions, neuromodulation and neuroprotection via adenosine and oxytocin receptors also decrease with age. On the other hand, receptors related to inflammation, oxidative stress and excitotoxicity have their densities increased with aging ([Figure 4](#F4){ref-type="fig"}).

![Major alterations in G~o/i~-coupled GPCRs' pathways in the aged brain, affecting four main areas. In the frontal lobe, particularly at the pre-frontal cortex **(1)**, the protein densities and/or affinity of α2 adrenoceptors, acetylcholine M2 receptors (M2), serotonin 5-HT1A receptors, opioid receptors (including the kappa receptor, κ), somatostatin receptors (SSTRs), cannabinoid receptor CB1, the metabotropic GABA~B~ receptor, and of the Gα proteins G~αo/i~, are found decreased. The same occurs in the **(2)** striatum, excluding the serotonin 5-HT1A receptors, the GABA metabotropic receptors and Gαo/i, and including dopamine D2 receptors and the oxytocin (OT) receptors. The **(3)** hippocampus also presents decreases in the same receptors as the frontal cortex, with the exclusion of the adrenoceptors and the GABA~B~ receptor. Contrarily, mGluR2 and 3 glutamate receptors are up-regulated in these three brain areas. In the **(4)** substantia nigra, dopamine D2, opioid κ and cannabinoid CB1 receptors are also depleted with age, while angiotensin AT1 receptor levels are increased.](fnagi-11-00089-g004){#F4}

Since GPCRs are the largest family of transmembrane receptors in humans and regulate several physiological functions, and given that the heterotrimeric G~i/o~ family is the most abundant in brain, these alterations significantly impair signal transduction and lead to (or aid on) age-related senescence processes and neuropathologies. With an increased aged population, the G~i/o~-coupled GPCRs signaling pathways are thus to be seriously considered as targets to attempt to revert the decline in cognitive and motor functions associated with senescence, as well as increased sensitivity to neurodegeneration at advanced ages.
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